AstraZeneca PLC (BCBA:AZN)

Market Cap	406.75T
Revenue (ttm)	79.66T
Net Income (ttm)	12.88T
Shares Out	n/a
EPS (ttm)	8,248.60
PE Ratio	31.58
Forward PE	n/a
Dividend	795.69 (1.17%)
Ex-Dividend Date	Aug 8, 2025

Volume	214
Average Volume	271
Open	68,200
Previous Close	68,650
Day's Range	68,100 - 68,500
52-Week Range	35,700 - 79,800
Beta	n/a
RSI	53.19
Earnings Date	Feb 10, 2026

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B...

• Industry: Pharmaceutical Preparations
• Founded: 1992
• Employees: 94,300
• Stock Exchange: Buenos Aires Stock Exchange
• Ticker Symbol: AZN

Financial Performance

In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.

Financial numbers in USD